secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-208912
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

RxSight Reports Q1 2026 Sales of $30.9M, Net Loss Widens, Reiterates Full-Year Guidance
--------------------------------------------------------------------------------

- Q1 2026 sales of $30.9M, down 18.5% YoY, driven by 27,472 Light Adjustable Lens units sold.
- 20 Light Delivery Devices sold in Q1, expanding installed base to 1,154 units.
- Net loss of $(15.9)M ($(0.38)/share) vs $(8.2)M ($(0.20)/share) in Q1 2025.
- Cash, equivalents and short-term investments totaled $217.9M as of March 31, 2026.
- 2026 revenue guidance reiterated at $120M-$135M; gross margin 70%-72%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000119312526208912/0001193125-26-208912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000119312526208912/rxst-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-208912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer